Osteosarcoma: Oncologic and functional results. A single institutional report covering 22 years

Renard, A.; Veth, R.P.H.; Schreuder, H.W.B.; Pruszczyński, M; Bökkerink, J.P.M.; Hoesel, Q.G.C.M. van; Staak, F.H.J.M. van der

doi:10.1002/(sici)1096-9098(199911)72:3<124::aid-jso3>3.0.co;2-g

Cited by 23 publications

(28 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some reports [2,6,10,17,19] of patients with pelvic osteosarcoma are from single institutions. Although these studies show overall survival (OS) rates ranging only from 19% to 47% [2,6,10,17,19], it is unclear whether this prognosis is universal for all patients or specific to those institutions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group

Isakoff

Barkauskas

Ebb

et al. 2012

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background The pelvis is an infrequent site of osteosarcoma and treatment requires surgery plus systemic chemotherapy. Poor survival has been reported, but has not been confirmed previously by the Children's Oncology Group (COG). In addition, survival of patients with pelvic osteosarcomas has not been compared directly with that of patients with nonpelvic disease treated on the same clinical trials. Questions/purposes First, we assessed the event-free (EFS) and overall survival (OS) of patients with pelvic osteosarcoma treated on COG clinical trials. We then asked whether patient survival compared with that of patients treated on the same clinical trials with nonpelvic disease. Finally, we asked whether patients with metastatic disease at initial diagnosis had worse survival. Methods We retrospectively reviewed data from 1054 patients with osteosarcoma treated in four studies between 1993 and 2005. Twenty-six of the 1054 patients (2.5%) had a primary tumor of the pelvis. At diagnosis, nine patients had metastatic disease. The minimum followup was 2 months (mean, 34 months; range, 2-102 months). Results Two of the nine patients with metastatic disease at diagnosis and five of the 17 with localized disease were alive at last contact. Estimates of the 5-year EFS for localized versus metastatic disease of the pelvis were 22% versus 23%. OS for patients with localized versus metastatic disease was 47% versus 22%. Patients with osteosarcoma in all other locations had a 5-year EFS of 57% and OS of 69%. Conclusions Our analysis confirms poor survival for patients with pelvic osteosarcoma. Survival with metastatic disease in the absence of a pelvic primary tumor is similar

show abstract

Section: Introductionmentioning

confidence: 99%

“…Although these studies show overall survival (OS) rates ranging only from 19% to 47% [2,6,10,17,19], it is unclear whether this prognosis is universal for all patients or specific to those institutions. European and Asian cooperative groups reported 5-year OS of almost 30% [7,13,16].…”

Section: Introductionmentioning

confidence: 99%

Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group

Isakoff

Barkauskas

Ebb

et al. 2012

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…With current use of adjuvant and neoadjuvant chemotherapy including doxorubicin, methotrexate, cisplatin and vincristine, the 5-year survival rate for OS varies from 50-65%. [1][2][3][4] However, OS is one of the most morphologically heterogeneous tumors with different degrees of malignancy, so some of the patients still encounter therapeutic failures. 5 The prognosis is tightly correlated to the presence of metastases, which typically develop in the lung.…”

Section: Introductionmentioning

confidence: 99%

Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines

Oshima

Sasaki²,

Negishi³

et al. 2007

Cancer Biology & Therapy

View full text Add to dashboard Cite

Osteosarcoma (OS) is one of the most common malignancies of the bone. Although prognosis of OS has improved significantly during the past several years due to more intensive chemotherapy and radiotherapy regimens, new therapeutic approaches are needed for recurrent and inoperable cases. p73 and p63, like their homologue, the tumor suppressor p53, are able to induce apoptosis in several cell types. Here, we evaluated the antitumor effects of p73 and p63 on eleven different human OS cell lines. In vitro, adenovirus-mediated transduction of p63g induced apoptosis in OS cells that are resistant to p53-mediated apoptosis, while less effect was observed following transduction of p73a or p63a. Interestingly, the apoptotic effects of p63g were greater than those of wild-type p53 in OS cells carrying MDM2-amplification. We then determined the in vivo therapeutic effect of intratumoral injection of adenovirus-vector expressing p53 family members on xenografts derived from Saos-2 cells implanted in nude mice, and showed that infection with p63g significantly suppressed tumor growth compared with p53. In addition, exogenous p73b and p63g significantly increased the chemosensitivity of OS cells to doxorubicin and cisplatin, chemotherapeutic agents commonly used in the treatment of OS. Our results suggest that adenovirus-mediated transduction of p53 family members may have utility in gene therapy for OS, particularly in combination with chemotherapeutic agents.

show abstract

“…Localized tumors limited to the bone of origin have the best prognosis; 5-year survival varies between 60-75% (4,89,90,98,124,134). Patients with metastatic disease (20% at presentation) are typically treated by surgical resection of the primary tumor.…”

Section: Introduction Osteosarcomamentioning

confidence: 99%

Evolving gene therapy approaches for osteosarcoma using viral vectors: Review

Witlox

Lamfers

Wuisman

et al. 2007

Bone

View full text Add to dashboard Cite

Osteosarcoma: Oncologic and functional results. A single institutional report covering 22 years

Cited by 23 publications

References 39 publications

Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group

Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children’s Oncology Group

Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines

Evolving gene therapy approaches for osteosarcoma using viral vectors: Review

Contact Info

Product

Resources

About